France’s Antabio extends its Series A financing round

French biopharma company Antabio has extended its Series A financing round with an additional 5.2 million euros ($6.1 million) from new investors to add to the 7.3 million euros ($8.5 million) raised in the first closing last year.

The new funding, from Omnes, BNP Paribas Développment and Sham Innovation Santé, will be used to accelerate the development of Antabio’s novel inhibitor of bacterial metallo ß-lactamases.

Antabio said that extension to its series A provides solid financial means for the company to take its innovative program into the clinic and move closer to this goal.

In July 2017, Antabio was awarded with CARB-X grant of up to $8.9 million to support the company’s inhibitor programme for the treatment of chronic infections in cystic fibrosis patients.